Skip to main content

This job has expired

Postdoctoral Fellow - Investigating Epi-transcriptomic Mechanisms in Cancer Progression

Oslo University Hospital, Department of Microbiology
Oslo, Østlandet (NO)
Minimum 53,000 USD
Closing date
27 Mar 2024

View more

Health Science
Job Type
Employment - Hours
Full time
Fixed term

2 positions available as Post-doc. The postdoctoral positions will commence in spring of 2024, and will extend over a minimum of 3 years upon a successful evaluation period. 

We are interested in the role of RNA modifications on cancer cell biology at single cell resolution, and in a patient relevant setting. Recent pioneering work has shown the significance of epi-transcriptomic regulation in cancer progression, and the field is expanding rapidly. We are looking for enthusiastic and determined individuals who can work both independently as well as in a group environment. These research posts will focus on characterizing novel mechanisms of gene regulation, and identify the prognostic power of RNA modifications in cancer progression.

Oslo University Hospital is a workplace with great diversity. We believe this is absolutely crucial to solving the tasks required of us. We therefore want this diversity to be reflected among the applicants for our positions and encourage everyone to apply regardless of who you are and what background you have. 


The successful candidates are capable of conceptual thinking, are looking forward to learning new techniques, have good communication skills and are well organized. Knowledge and prior documented application of at least one of the following is a requirement: (1) High-throughput sequencing (Single cell RNA-seq, DRIP-Seq, ChIP-Seq, RIP-seq) and molecular/biochemical characterization in cancer and/or (2) application of patient derived cancer models (organoid/ xenograft). Potential candidates have completed (or are close to completing) a PhD degree in molecular biology or medicine, with one or several publications in internationally well-regarded, peer-reviewed scientific journals as the second requirement. Applicants with evidence of publications in press will also be considered.

For consideration, only interested persons with the above experience and skill set, should submit the following documents (note that applications lacking any of these three requirements will be terminated without further evaluation):

1) A concise application letter explaining your motivation for this position (1-2 pages).

2) Curriculum vitae including a list of peer-reviewed publications.

3) Contact information of three references.

The postdoctoral positions will commence in Spring of 2024 and will extend over a minimum of 3 years upon a successful evaluation period. A selection committee will contact chosen candidates two weeks after the closing deadline for interviews. Oslo University Hospital is an equal opportunity employer.

Relevant References:

N6-Methyladenosine (m6A) Depletion Regulates Pluripotency Exit by Activating Signaling Pathways in Embryonic Stem Cells. Jin K, Zuo H, Klungland A, Anastassiadis K, Marr C & Filipczyk A. Proc. Natl. Acad. Sci. U S A (PNAS), 118 (51), December, 2021.

Su Z, Monshaugen I, Wilson B, Wang F, Klungland A, Ougland R, Dutta A. TRMT6/61A-dependent base methylation of tRNA-derived fragments regulates gene-silencing activity and the unfolded protein response in bladder cancer. Nature Communications. 2022 Apr 20;13(1):2165.

Reversible RNA modifications in meiosis and pluripotency. Klungland A, Dahl JA, Greggains G, Fedorcsak P, Filipczyk A. Nat Methods. 2017 Jan 29;14(1):18-22.


Get job alerts

Create a job alert and receive personalised job recommendations straight to your inbox.

Create alert